

# Advances in Metastatic Triple Negative Breast Cancer: Immunotherapy, Antibody Drug Conjugates, and Beyond

Jane Lowe Meisel, MD


Associate Professor of Hematology and Oncology Winship Cancer Institute of Emory University Emory University School of Medicine

### **Triple negative breast cancer (TNBC)**

- TNBC accounts for 20% of breast cancers worldwide
  - Almost 200,000 cases per year
- More commonly diagnosed in women younger than 40, disproportionately affects black women and carriers of *BRCA1* genetic mutations
- TNBC typically presents aggressively and has a poorer prognosis compared with other subtypes
  - 5-year survival for stage 4 disease = 12%
- Historically, given the absence of targeted therapy, the mainstay of treatment has been chemotherapy – but this is not enough

a. Gonzalez-Angulo AM, et al. Clin Cancer Res. 2011;17:1082-1089; b. Lin NU, et al. Cancer. 2012;118:5463-5472.

### An area of great need...but, incredible progress



More exciting things to come:

-PARP inhibitors outside of the BRCA+ population

-New antibody-drug conjugates


-ADCs + IO (possibility of expanding IO to PDL1- patients?)

# **PARP** inhibition

### **OlympiAD: Olaparib vs Chemotherapy**

### Eligibility

- Deleterious BRCA mutation
- Advanced *ERBB2* breast cancer
- Up to 2 previous lines of chemotherapy for metastatic disease (platinum allowed if no POD during treatment)
- Primary Endpoint
  - Investigator-assessed PFS




Stratification:

- Previous chemo for metastatic disease (y/n)
- HR status (+/-)
- Previous platinum-based therapy (y/n)

• Robson M, et al. N Engl J Med. 2017;377:523-533.

### **EMBRACA: Talazoparib vs Chemotherapy**

- Eligibility
  - Deleterious BRCA mutation
  - Advanced *ERBB2* breast cancer
  - Up to 2 previous lines of chemotherapy for metastatic disease
- Primary Endpoint
  - Investigator-assessed PFS




Stratification: -# of prior regimens (0 or >/ = 1) -HR status (+/-) -CNS mets (y/n)

• Litton JK, et al. *N Engl J Med*. 2018;379:753-763.

These materials are provided to you solely as an educational resource for your personal use. Any commercial use or distribution of these materials or any portion thereof is strictly prohibited.

### PARP Inhibitor Superior to Chemotherapy in *BRCA*mut MBC



#### • a. Robson M, et al. N Engl J Med. 2017;377:523-533; b. Litton J, et al. N Engl J Med. 2018;379:753-763.

These materials are provided to you solely as an educational resource for your personal use. Any commercial use or distribution of these materials or any portion thereof is strictly prohibited.

# Immunotherapy

### Cortes J, et al. ASCO 2020, Abs 1000.

### KEYNOTE-355: Pembrolizumab + Chemotherapy

#### Key Eligibility Criteria

- Age ≥18 years
- Central determination of TNBC and PD-L1 expression
- Previously untreated locally recurrent inoperable or metastatic TNBC
- Completion of treatment with curative intent ≥6 months prior to first disease recurrence
- ECOG performance status 0 or 1
- Life expectancy ≥12 weeks from randomization
- Adequate organ function
- No systemic steroids
- No active CNS metastases
- No active autoimmune disease

# Pembrolizumab<sup>a</sup> + Chemotherapy<sup>b</sup>

#### Placebo<sup>c</sup> + Chemotherapy<sup>b</sup>

Progressive disease<sup>d</sup>/cessation of study therapy

#### **Stratification Factors:**

R

2:1

- Chemotherapy on study (taxane vs gemcitabine/carboplatin)
- PD-L1 tumor expression (CPS  $\geq$ 1 vs CPS <1)
- Prior treatment with same class chemotherapy in the neoadjuvant or adjuvant setting (yes vs no)


<sup>a</sup>Pembrolizumab 200 mg intravenous (IV) every 3 weeks (Q3W) <sup>b</sup>Chemotherapy dosing regimens are as follows:

Nab-paclitaxel 100 mg/m<sup>2</sup> IV on days 1, 8, and 15 every 28 days Paclitaxel 90 mg/m<sup>2</sup> IV on days 1, 8, and 15 every 28 days Gemcitabine 1000 mg/m<sup>2</sup>/carboplatin AUC 2 on days 1 and 8 every 21 days 'Normal saline

<sup>d</sup>Treatment may be continued until confirmation of progressive disease


### **Keynote-355: Progression-Free Survival**

ITT



Statistical significance not tested due to prespecified hierarchical testing strategy


#### FDA approved 11/2020



**PD-L1 CPS ≥1** 

Prespecified *P* value boundary of 0.00111 not met


#### **PD-L1 CPS ≥10**



Prespecified *P* value boundary of 0.00411 met

### Keynote-355: PFS Subgroup Analysis by On-Study Chemotherapy

#### PD-L1 CPS ≥10



PD-L1 CPS ≥1						
Subgroup		N	Pembro	PFS (mo) Placebo + Chemo	Hazard Ratio for Progression or Death (95% CI)	
Overall	<b>—</b> —	636	7.6	5.6	0.74 (0.61 to 0.90)	
On-study chemotherapy						
Nab-Paclitaxel		204	6.3	5.3	0.66 (0.47 to 0.92)	
Paclitaxel 🛏		84	9.4	3.8	0.46 (0.26 to 0.82)	
Gemcitabine- Carboplatin	<b>—</b> —	<b></b> 348	7.5	7.5	0.86 (0.66 to 1.11)	
0.0 0.5 1.0 1.5 Hazard Ratio (95% CI)						
FavorsFavorsPembro + ChemoPlacebo + Chemo						

#### ITT


		Median I	PFS (mo)	Hazard Ratio for Progression	
Subgroup	N	Pembro- + Chemo	Placebo + Chemo	or Death (95% CI)	
Overall -	- 847	7.5	5.6	0.82 (0.69 to 0.97)	
On-study chemotherapy					
Nab-Paclitaxel	- 268	7.5	5.4	0.69 (0.51 to 0.93)	
Paclitaxel	┛ 114	8.0	3.8	0.57 (0.35 to 0.93)	
Gemcitabine-	465	7.4	7.4	0.93 (0.74 to 1.16)	
0.0 0.5 1.0 1.5 Hazard Ratio (95% CI)					
Favors Pembro + Chemo	Favo Placebo +				

• Slide adapted from Rugo H et al, SABCS 2020. GS3-01.

### **KEYNOTE 355 Overall Survival**

	Median OS (mo)					
Subgroup		Patients <i>n</i>	Pembro + Chemo	Patients <i>n</i>	Placebo + Chemo	Hazard Ratio (95% Cl)
Overall	-+	566	17.2	281	15.5	0.89 (0.76 to 1.05)
PD-L1 CPS <1		— 141	16.2	70	14.7	0.97 (0.72 to 1.32)
PD-L1 CPS 1-9		205	13.9	108	15.5	1.09 (0.85 to 1.40)
PD-L1 CPS 10-19		80	20.3	39	17.6	0.71 (0.46 to 1.09)
PD-L1 CPS ≥20		140	24.0	64	15.6	0.72 (0.51 to 1.01)
0.0	0.5 1.0 Hazard Ratio (95%	1.5 6 CI)				
		vors + Chemo				


 For pembrolizumab + chemotherapy in mTNBC, CPS ≥10 is the best cut-off to define those expected to benefit, and this is the standard of care for mTNBC with CPS≥10




# Antibody-drug conjugates

## Sacituzumab Govitecan (SG)

- Trop-2 is expressed in all subtypes of breast cancer and linked to poor prognosis<sup>[a]</sup>
- Distinct features of SG:<sup>[b]</sup>
  - Antibody highly specific for Trop-2
  - High drug-to-antibody ratio (7.6:1)
  - Internalization and enzymatic cleavage by tumor cell not required for the liberation of SN-38 from the antibody
  - Hydrolysis of the linker also releases the SN-38 cytotoxic extracellularly in the tumor microenvironment, providing a bystander effect



### **ASCENT: Sacituzumab Govitecan in Refractory/Relapsed mTNBC**




- Number of prior chemotherapies (2-3 vs >3)
- Geographic region (North America vs Europe)
- Presence/absence of known brain metastases (yes/no)
- Primary results including PFS and OS
- ASCENT was <u>halted early</u> due to compelling evidence of efficacy per unanimous DSMC recommendation

Bardia A, et al. Annals of Oncology (2020) 31 (suppl\_4): S1142-S1215.


### **ASCENT: Results**

#### PFS

#### OS



### T-DXd MOA, Bystander Effect, and Rationale for Targeting HER2-low mBC



 Results from a phase 1b study have reported efficacy of T-DXd in heavily pretreated patients (N = 54) with HER2-low mBC, with a mPFS of 11.1 months and an ORR of 37.0%<sup>3</sup>

HER2, human epidermal growth factor receptor 2; MOA, mechanism of action; mBC, metastatic breast cancer; mPFS, median progression-free survival; ORR, objective response rate; T-DXd, trastuzumab deruxtecan. 1. Nakada T, et al. *Chem Pharm Bull*. 2019;67:173-185. 2. Ogitani Y, et al. *Clin Cancer Res*. 2016;22:5097-5108. 3. Modi S, et al. *J Clin Oncol*. 2020;38:1887-1896. 17

# DESTINY-Breast04: First Randomized Phase 3 Study of T-DXd for HER2-low mBC

An open-label, multicenter study (NCT03734029)

#### **Patients**<sup>a</sup>

- HER2-low (IHC 1+ vs IHC 2+/ISH-), unresectable, and/or mBC treated with 1-2 prior lines of chemotherapy in the metastatic setting
- HR+ disease considered endocrine refractory

#### 

#### **Primary endpoint**

PFS by BICR (HR+)

#### Key secondary endpoints<sup>b</sup>


- PFS by BICR (all patients)
- OS (HR+ and all patients)

#### **Stratification factors**

- Centrally assessed HER2 status<sup>d</sup> (IHC 1+ vs IHC 2+/ISH-)
- 1 versus 2 prior lines of chemotherapy
- HR+ (with vs without prior treatment with CDK4/6 inhibitor) versus HR-


ASCO/CAP, American Society of Clinical Oncology/College of American Pathologists; BICR, blinded independent central review; CDK, cyclin-dependent kinase; DOR, duration of response; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; IHC, immunohistochemistry; ISH, in situ hybridization; mBC, metastatic breast cancer; OS, overall survival; PFS, progression-free survival; Q3W, every 3 weeks; R, randomization; T-DXd, trastuzumab deruxtecan; TPC, treatment of physician's choice. alf patients had HR+ mBC, prior endocrine therapy was required. bOther secondary endpoints included ORR (BICR and investigator), DOR (BICR), PFS (investigator), and safety; efficacy in the HR– cohort was an exploratory endpoint. CTPC was administered accordingly to the label. dPerformed on adequate archived or recent tumor biopsy per ASCO/CAP guidelines using the VENTANA HER2/neu (485) investigational use only [IUO] Assay system.

### **PFS and OS in HR- (Exploratory Endpoints)**



HR, hormone receptor; mOS, median overall survival; mPFS, median progression-free survival; OS, overall survival; PFS, progression-free survival; T-DXd, trastuzumab deruxtecan; TPC, treatment of physician's choice. For efficacy in the hormone receptor–negative cohort, hormone receptor status is based on data from the electronic data capture corrected for misstratification.

### **Confirmed ORR**




#### Confirmed Objective Response Rate

#### Hormone receptor status is based on data from the electronic data capture corrected for misstratification.

ORR, objective response rate; T-DXd, trastuzumab deruxtecan; TPC, treatment of physician's choice.

<sup>a</sup>The response of 1 patient was not confirmed. <sup>b</sup>Clinical benefit rate is defined as the sum of complete response rate, partial response rate, and more than 6 months' stable disease rate, based on blinded independent central review.

### Where does this leave us?




### **Case presentation**

 45F presents with a breast mass that is biopsied and found to be triple negative invasive ductal carcinoma (ER-PR- HER2 1+). During her workup, she is found to have a liver mass that is biopsied and is found to be metastatic breast cancer, also triple negative. PD-L1 CPS score is 13. Genetic testing is done and she is *BRCA* negative.

### What would your recommendation be?

- a) Initiate trastuzumab deruxtecan
- b) Initiate taxane/pembrolizumab
- c) Initiate olaparib
- d) Initiate sacituzumab govitecan
- e) Initiate a taxane

### **Treatment of metastatic TNBC**



### On the horizon

- PARP inhibitors outside of the BRCA+ population
- New antibody-drug conjugates
- ADCs + IO (possibility of expanding IO to PDL1patients?)




### **TBCRC 048: OLAPARIB EXPANDED** Benefit in g*PALB2* + s*BRCA*

PALB2 N=13	sBRCA1/2 N=17	ATM & CHEK2** N=17
Germline: 9/11 PR (82%) 10/11 had tumor regression; 1 SD > 1 yr	8/16 PR (50%)	0/13 germline 0/4 somatic
Somatic: 0/2 – both SD* (limited assessments)		

New cohorts are beginning for gPALB2 and sBRCA1/2 breast cancer

• Tung N, et al. J Clin Oncol 38: 2020 (suppl; abstr 1002).


# Datopotamab deruxtecan (Dato-DXd, DS-1062a)



Datopotamab deruxtecan (Dato-DXd) showed potent antitumor activity against TROP2-expressing tumors by efficient payload delivery into tumors

### **TROPION-PanTumor01: Study Design**

#### Phase 1 Trial: Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer



ECOG PS, Eastern Cooperative Oncology Group performance status; Q3W, every 3 weeks; RECIST, Response Evaluation Criteria in Solid Tumors.

<sup>a</sup> Pretreatment tumor tissue was required for retrospective analysis of TROP2 expression. <sup>b</sup> Results from the NSCLC cohort have been previously reported.<sup>1,2</sup> <sup>c</sup> Includes patients treated in the dose-escalation and dose-expansion portions. <sup>d</sup> Enrollment in the HR+/HER2- cohort is now complete and data will be forthcoming. <sup>e</sup>Exploratory objectives include analyses of biomarkers associated with response. <sup>f</sup> Response assessments are based on RECIST 1.1.


1. Garon E, et al. WCLC 2021. Abstract 156; 2. Meric-Bernstam F, et al. ASCO 2021.

Krop I, et al. Presented at: SABCS 2021. Abstract GS1-05.


These materials are provided to you solely as an educational resource for your personal use. Any commercial use or distribution of these materials or any portion thereof is strictly prohibited.

# **TROPION-PanTumor01: Antitumor Responses by BICR**

### All Patients With TNBC



### Patients With TNBC Without Prior Topo I Inhibitor-Based ADC



#### Krop I, et al. Presented at: SABCS 2021. Abstract GS1-05.

These materials are provided to you solely as an educational resource for your personal use. Any commercial use or distribution of these materials or any portion thereof is strictly prohibited.

### **Datopotamab: next steps**

- Being studied as front-line therapy for mTNBC that is not PD-L1+ (against physician's choice chemotherapy) (TROPION-Breast 02)
- Being studied in combination with durvalumab for patients with triple negative breast cancer as one arm of BEGONIA
- Being studied for ER+ pretreated mBC (TROPION-Breast 01)

### Ladiratuzumab vedotin (LV)


- LIV-1 is a transmembrane protein involved in the signaling pathway leading to epithelial-mesenchymal transition (EMT) and expression has been linked with malignant progression to metastasis in breast cancer<sup>1,3</sup>
- LIV-1 is expressed in ≥90% of all clinical subtypes of metastatic breast cancer tumors with low expression in normal tissues<sup>4</sup>



1. Lue H-W, et al. PLOS One. 2011;6(11):e27720.


- 2. Hogstrand C, et al. Biochem J. 2013;455:229-37.
- 3. Manning DL, et al. Eur J Cancer. 1994;30A(5):675-8.

4. Sussman D, et al. Mol Cancer Ther. 2014;13(12):2991-3000.



Ladiratuzumab vedotin is an investigational agents, and its safety and efficacy have not been established.

### Rationale for Combining LV with Pembrolizumab



Ladiratuzumab vedotin is an investigational agents, and its safety and efficacy have not been established.

Abbreviations: LV, ladiratuzumab vedotin

1. Cao A, et al. Cancer Res. 2018;78(13 Suppl):Abstract 2742.

Jane Meisel. Phase 1b/2 Study of Ladiratuzumab Vedotin (LV) in Combination with Pembrolizumab for First-Line Treatment of Triple-Negative Breast Cancer (SGNLVA-002, Trial in Progress)

### **Current Study Design**

- SGNLVA-002 (NCT03310957) is an ongoing global single-arm, open-label, phase 1b/2 study of LV + pembrolizumab as 1L therapy for patients with unresectable locally advanced or mTNBC
- LV 1.5 mg/kg administered on Day 1 and Day 8 (off Day 15) of every 21-day cycle in combination with pembrolizumab administered on Day 1 of every cycle
  - Rationale for the combination: LV-induced immunogenic cell death elicits an inflammatory response, leading to enhanced antitumor immunity, antigen presentation, and tumor cell immune infiltration
- Eligible patients have metastatic TNBC, no prior cytotoxic treatment in the metastatic setting, tumor tissue PD-L1 CPS <10 using the PD-L1 IHC 22C3 clone, and at least 6 months since prior treatment with curative intent

### Conclusions

- Triple negative breast cancer has come a long way in the past few years, with more breakthroughs on the way
- Many more options for patients, and options that offer more longevity as well as better quality of life
- The future: defining TNBC by what it is (gBRCA, HER2-low, PD-L1+, etc) rather than by what it is not!



### **Thank you!**

# EMORY WINSHIP CANCER INSTITUTE

National Cancer Institute-Designated Comprehensive Cancer Center

